摘要
目的 :评估尿核基质蛋白 2 2 (NMP2 2 )测定作为尿路上皮癌肿瘤标记物的临床应用价值。方法 :应用免疫酶标记法 (ELISA)检测 58例尿路上皮癌、32例良性泌尿系疾病、1 8例其他恶性肿瘤和 2 0例健康志愿者尿中 NMP2 2水平。尿路上皮癌组中有 2 9例患者在术后 5～ 7d再次检测其尿 NMP2 2。结果 :尿路上皮癌组的尿 NMP2 2平均为 2 9.4× 1 0 3u/L,明显高于良性泌尿系疾病组 (1 0 .1× 1 0 3u/L )、其他恶性肿瘤组 (8.6× 1 0 3u/L)和健康志愿者组 (5.7× 1 0 3u/L) (P <0 .0 0 1 ) ;尿路上皮癌患者尿 NMP2 2随肿瘤病理分级的递增而升高 ;复发病例 (46.9× 1 0 3u/L )高于初发病例 (2 1 .3× 1 0 3u/L ) (P <0 .0 1 ) ;2 9例尿路上皮癌患者术后复测尿 NMP2 2 ,结果较术前明显下降。结论 :尿 NMP2 2作为尿路上皮癌的肿瘤标记物具有较高的特异性 ,并可在一定程度上反应肿瘤的恶性程度和预后。
purpose:To evaluate primarily the ability of urinary level of nuclear matrix protein 22 (NMP22) as a tumor marker for the diagnosis of urothelial cancer.Methods:Urinary NMP22 values were determined for 58 patients with urothelial transitional cell carcinomas (TCC),32 with benign urological diseases,18 with other cancers and 20 healthy volunteers by an enzyme-linked immunosorbent assay (ELISA);29 of 58 patients with urothelial cancers were determined for urinary NMP22 value at 5～7 days postoperatively again.Results:The median NMP22 value of urothelial cancer was 29.4 ×10 3 u/L,significantly higher than those of benign urological disease ( 10.1 ×10 3 u/L),other cancer ( 8.6 ×10 3 u/L) and healthy volunteer( 5.7 ×10 3 u/L)(P< 0.001 );The NMP22 values of patients with urothelial cancers were elevated with tumors′ pathologic grades increase;The values in recurent cases ( 46.9 ×10 3 u/L) was higher than those in original cases ( 21.3 ×10 3 u/L)(P< 0.01 );For 29 patients with urothelial cancer determined again postoperatively,their median urinary NMP22 value decreased remarkably in comparison with preoperation.Conclusions:Urinary NMP22 is a very specific tumor marker for the diagnosis of urothelial cancers and can indicate partially tumor′s malignancy degree and prognosis.
出处
《临床泌尿外科杂志》
2000年第9期392-394,共3页
Journal of Clinical Urology
